SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Letter to the Editor

Split Viewer

Blood Res 2014; 49(2):

Published online June 25, 2014

https://doi.org/10.5045/br.2014.49.2.130

© The Korean Society of Hematology

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy

Pasquale Niscola1*, Andrea Tendas1, Laura Scaramucci1, Roberta Merola2, Gianfranco Catalano1, and Paolo de Fabritiis1

Author Info. +

1Hematology Unit, S. Eugenio Hospital, Rome, Italy.

2Department of Clinical Pathology (Cytogenetic Unit), Regina Elena Cancer Institute, Rome, Italy.

Correspondence to : Pasquale Niscola. Hematology Unit, Piazzale dell'Umanesimo 10, 00144 Rome, Italy. pniscola@gmail.com

Received: February 5, 2014; Revised: March 12, 2014; Accepted: May 15, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

Go to
  1. Giagounidis, AA, Haase, S, Heinsch, M, Gohring, G, Schlegelberger, B, Aul, C. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol, 2007;86;133-137.
    Pubmed
  2. Breccia, M, Cannella, L, Latagliata, R, et al. Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome. J Clin Oncol, 2011;29;e402-e403.
    Pubmed
  3. Cannella, L, Latagliata, R, Breccia, M, et al. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol, 2012;91;309-310.
    Pubmed
  4. Vigna, E, Recchia, AG, Cuzzola, M, Morabito, L, Gentile, M, Morabito, F. Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?. Leuk Lymphoma, 2014;55;1408-1409.
    Pubmed
  5. Oliva, EN, Schey, C, Hutchings, AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res, 2011;1;160-166.
    Pubmed
  6. Gattermann, N, Finelli, C, Della Porta, M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica, 2012;97;1364-1371.
    Pubmed
  7. Molica, M, Salaroli, A, Alimena, G, Breccia, M. Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. Blood Transfus, 2014;12;s162-s163.
    Pubmed
  8. Greenberg, P, Cox, C, LeBeau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997;89;2079-2088.
    Pubmed
  9. Malcovati, L, Germing, U, Kuendgen, A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol, 2007;25;3503-3510.
    Pubmed
  10. Niscola, P, Vischini, G, Tendas, A, et al. Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther, 2011;11;415-432.
    Pubmed

Article

Letter to the Editor

Blood Res 2014; 49(2): 130-137

Published online June 25, 2014 https://doi.org/10.5045/br.2014.49.2.130

Copyright © The Korean Society of Hematology.

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy

Pasquale Niscola1*, Andrea Tendas1, Laura Scaramucci1, Roberta Merola2, Gianfranco Catalano1, and Paolo de Fabritiis1

1Hematology Unit, S. Eugenio Hospital, Rome, Italy.

2Department of Clinical Pathology (Cytogenetic Unit), Regina Elena Cancer Institute, Rome, Italy.

Correspondence to: Pasquale Niscola. Hematology Unit, Piazzale dell'Umanesimo 10, 00144 Rome, Italy. pniscola@gmail.com

Received: February 5, 2014; Revised: March 12, 2014; Accepted: May 15, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. Giagounidis, AA, Haase, S, Heinsch, M, Gohring, G, Schlegelberger, B, Aul, C. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol, 2007;86;133-137.
      Pubmed
    2. Breccia, M, Cannella, L, Latagliata, R, et al. Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome. J Clin Oncol, 2011;29;e402-e403.
      Pubmed
    3. Cannella, L, Latagliata, R, Breccia, M, et al. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol, 2012;91;309-310.
      Pubmed
    4. Vigna, E, Recchia, AG, Cuzzola, M, Morabito, L, Gentile, M, Morabito, F. Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?. Leuk Lymphoma, 2014;55;1408-1409.
      Pubmed
    5. Oliva, EN, Schey, C, Hutchings, AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res, 2011;1;160-166.
      Pubmed
    6. Gattermann, N, Finelli, C, Della Porta, M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica, 2012;97;1364-1371.
      Pubmed
    7. Molica, M, Salaroli, A, Alimena, G, Breccia, M. Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. Blood Transfus, 2014;12;s162-s163.
      Pubmed
    8. Greenberg, P, Cox, C, LeBeau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997;89;2079-2088.
      Pubmed
    9. Malcovati, L, Germing, U, Kuendgen, A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol, 2007;25;3503-3510.
      Pubmed
    10. Niscola, P, Vischini, G, Tendas, A, et al. Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther, 2011;11;415-432.
      Pubmed
    Blood Res
    Volume 59 2024
    Current Issue Archives

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download